Daniel has over 20 years of experience as a leader in the Life Sciences industry, implementing significant disruptive programs that have revolutionized clinical trial conduct. Daniel’s solutions are based on the premise that Pharmaceutical and Biotechnology companies need to maintain core competencies in-house and outsource non-core competencies, and that the ideal operating scenario involved an integrated methodology (providing sponsors with transparency and allowing them to maintain strategic control).
Daniel brought the Functional Service Provider (FSP) model (1998) and Embedded Solutions model (2009) to the industry. For his work, Daniel was awarded the Industry Innovation Award in 2012.
Daniel founded ReSearch Pharmaceutical Services, Inc. (RPS) in 1998 and was its Chairman and Chief Executive Officer through 2013. Under Daniel’s leadership, RPS grew to approximately $500 million in annual revenue and 5,000 employees operating in over 70 countries by 2013. RPS established itself as a top tier global Contract Research Organization (CRO) with an annualized compounded growth rate of greater than 30%.
RPS went public on the London Alternative Investment Market in 2008, and was subsequently listed on NASDAQ. RPS was acquired by the private equity firm Warburg Pincus in 2011, and subsequently purchased by KKR in 2013 at which time the organization was merged with PRA.
Prior to starting RPS, Daniel served as Executive Vice President of Operating Specialties for Kforce, Inc. from 1993 to 1998. Daniel established and subsequently grew the Pharmaceutical Division, Healthcare Division, Engineering Division, Scientific Division, Legal Division, and Human Resources Division. Kforce’s revenue grew from approximately $50M in 1995 to approximately $1 billion in 1998.
Originally from the Philadelphia area, Daniel graduated from The Haverford School (1974) and from the University of Pennsylvania, Wharton School of Business (1979).